Cornerstone Capital Management Holdings LLC. lessened its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 34.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 93,539 shares of the medical instruments supplier’s stock after selling 49,000 shares during the quarter. Cornerstone Capital Management Holdings LLC. owned about 0.49% of LeMaitre Vascular worth $2,920,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of LMAT. Bank of New York Mellon Corp lifted its position in shares of LeMaitre Vascular by 1.6% during the 1st quarter. Bank of New York Mellon Corp now owns 88,552 shares of the medical instruments supplier’s stock worth $2,181,000 after buying an additional 1,408 shares during the last quarter. Ameriprise Financial Inc. lifted its position in shares of LeMaitre Vascular by 52.3% during the 1st quarter. Ameriprise Financial Inc. now owns 201,508 shares of the medical instruments supplier’s stock worth $4,963,000 after buying an additional 69,186 shares during the last quarter. Prudential Financial Inc. lifted its position in shares of LeMaitre Vascular by 2.1% during the 1st quarter. Prudential Financial Inc. now owns 97,350 shares of the medical instruments supplier’s stock worth $2,398,000 after buying an additional 2,040 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of LeMaitre Vascular during the 1st quarter worth approximately $353,000. Finally, American International Group Inc. lifted its position in shares of LeMaitre Vascular by 7.0% during the 1st quarter. American International Group Inc. now owns 8,310 shares of the medical instruments supplier’s stock worth $205,000 after buying an additional 545 shares during the last quarter. Institutional investors and hedge funds own 66.34% of the company’s stock.

In related news, CEO George W. Lemaitre sold 10,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.62, for a total transaction of $336,200.00. Following the transaction, the chief executive officer now directly owns 3,436,808 shares in the company, valued at $115,545,484.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Lawrence J. Jasinski sold 6,500 shares of the firm’s stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $34.47, for a total value of $224,055.00. Following the transaction, the director now owns 12,863 shares in the company, valued at $443,387.61. The disclosure for this sale can be found here. Insiders have sold 373,121 shares of company stock worth $12,825,992 over the last 90 days. 23.70% of the stock is currently owned by company insiders.

WARNING: “LeMaitre Vascular, Inc. (LMAT) Stake Decreased by Cornerstone Capital Management Holdings LLC.” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/10/17/lemaitre-vascular-inc-lmat-stake-decreased-by-cornerstone-capital-management-holdings-llc.html.

Several brokerages have recently weighed in on LMAT. Canaccord Genuity restated a “hold” rating and set a $30.00 price objective on shares of LeMaitre Vascular in a research report on Monday, October 9th. Zacks Investment Research downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Thursday, September 28th. BidaskClub downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Wednesday, August 23rd. Stifel Nicolaus restated a “buy” rating and set a $32.00 price objective (up previously from $29.00) on shares of LeMaitre Vascular in a research report on Sunday, July 30th. Finally, Benchmark Co. raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, July 28th. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. LeMaitre Vascular presently has an average rating of “Hold” and a consensus price target of $32.00.

LeMaitre Vascular, Inc. (LMAT) opened at 37.08 on Tuesday. The firm has a market capitalization of $705.34 million, a PE ratio of 52.97 and a beta of 0.67. LeMaitre Vascular, Inc. has a one year low of $18.55 and a one year high of $39.29. The stock has a 50 day moving average of $37.56 and a 200-day moving average of $31.81.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $0.23 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.17 by $0.06. LeMaitre Vascular had a return on equity of 15.02% and a net margin of 14.19%. The firm had revenue of $25.80 million for the quarter, compared to analysts’ expectations of $25.42 million. During the same period last year, the business posted $0.14 earnings per share. The firm’s revenue for the quarter was up 15.2% on a year-over-year basis. On average, equities analysts predict that LeMaitre Vascular, Inc. will post $0.80 EPS for the current year.

LeMaitre Vascular announced that its board has initiated a share repurchase plan on Thursday, July 27th that authorizes the company to repurchase $7.50 million in outstanding shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 1.4% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s board believes its stock is undervalued.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Institutional Ownership by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with MarketBeat.com's FREE daily email newsletter.